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The expansion of polyglutamine tracts in a variety of proteins causes devastating, dominantly inherited
neurodegenerative diseases, including six forms of spinal cerebellar ataxia (SCA). Although a polyglutamine
expansion encoded in a single allele of each of the responsible genes is sufficient for the onset of each disease, clinical
observations suggest that interactions between these genes may affect disease progression. In a screen for modifiers
of neurodegeneration due to SCA3 in Drosophila, we isolated atx2, the fly ortholog of the human gene that causes a
related ataxia, SCA2. We show that the normal activity of Ataxin-2 (Atx2) is critical for SCA3 degeneration and that
Atx2 activity hastens the onset of nuclear inclusions associated with SCA3. These activities depend on a conserved
protein interaction domain of Atx2, the PAM2 motif, which mediates binding of cytoplasmic poly(A)-binding protein
(PABP). We show here that PABP also influences SCA3-associated neurodegeneration. These studies indicate that the
toxicity of one polyglutamine disease protein can be dramatically modulated by the normal activity of another. We
propose that functional links between these genes are critical to disease severity and progression, such that
therapeutics for one disease may be applicable to others.
Citation: Lessing D, Bonini NM (2008) Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol 6(2): e29. doi:10.
1371/journal.pbio.0060029
Introduction
The polyglutamine diseases are caused by the expansion of
a CAG repeat encoding glutamine within the open reading
frames of at least nine genes [1]. The disease state is thought
to be due to a misfolded conformation of the pathogenic
protein (termed an Ataxin in most forms of spinal cerebellar
ataxia [SCAs]), which accumulates intracellularly in ubiquiti-
nated inclusions along with chaperones and subunits of the
proteasome [2]. Among the SCAs, there is a remarkable
overlap of symptoms, including progressive loss of gait and
limb muscle coordination, with neurodegeneration in the
cerebellum and often select brainstem nuclei [3].
In addition to the shared mechanism of mutation and
clinical phenotypes, there are intriguing hints of interactions
between the polyglutamine genes that cause different SCAs.
For example, relatively long CAG repeat lengths (still within
the normal range) in the causative gene for SCA6 are
correlated with an early age of onset of SCA2 [4]. In addition,
there are a number of such observations suggesting links
between SCA2 and SCA3 diseases. The severity of facial
muscle twitch in patients with SCA3 is correlated with the
length of the CAG repeat in the normal alleles of the SCA2
gene ATXN2 [5]. Both SCA2 and SCA3 are unusual among the
dominantly inherited ataxias in that they can manifest with
parkinsonism [6]. Finally, the normal Ataxin-2 (Atx2) protein
can be detected in the pathogenic inclusions of SCA3
patients, and, likewise, normal Atx3 protein localizes to the
inclusions formed in SCA2 patients [7].
Several SCAs have been successfully modeled in Drosophila
[8–10], an organism ideally suited to screen for genes that can
modify the effects of protein toxicity and neurodegeneration.
Moreover, up-regulation of atx2, the Drosophila ortholog of
the human gene that causes SCA2 disease, has been shown to
enhance the toxicity of human disease forms of SCA1 and
SCA3 in ﬂies [11]. Many genes that modify SCA1 toxicity in
the ﬂy, including atx2, have been shown to encode proteins
that interact directly with pathogenic Atx1, and further, these
proteins form an interaction network that includes Atx3 [12].
Taken together with the clinical data, this work suggests that
interactions between CAG-containing genes may occur that
inﬂuence disease.
Despite these ﬁndings, the molecular activities of the Atx2
and Atx3 proteins do not indicate obvious functional links
between these two particular CAG repeat genes. Atx2 is a
cytoplasmic protein with an RNA-binding Lsm domain and a
PAM2 motif that binds speciﬁcally to the PABC domain of
proteins such as the cytoplasmic poly(A)-binding protein
(PABP) [13,14]. PABP and Atx2 directly interact in Caeno-
rhabditis elegans [15]; and in ﬂies and cultured cells, PABP and
Atx2 also physically associate and co-sediment with poly-
ribosomes [16]. In contrast, Atx3 shuttles between the
cytoplasm and nucleus, contains ubiquitin interaction motifs
and de-ubiquitination activity [17–20], and is normally
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tional proteasome [21].
In a screen in Drosophila for modiﬁers of degeneration
induced by the human pathogenic protein causing SCA3, we
identiﬁed atx2. Up-regulation of atx2 synergistically enhanced
SCA3 degeneration, and strikingly, we found that the
endogenous activity of atx2 modulates progression of neuro-
degeneration induced by pathogenic Atx3. Thus, toxicity of
the polyglutamine disease protein Atx3 is critically depend-
ent upon the normal activity of atx2, a second gene associated
with polyglutamine disease in humans. These ﬁndings under-
score the power of the Drosophila system, and provide a
foundation for further molecular insight into human genetic
and clinical studies.
Results
Up-Regulation of Atx2 Synergistically Enhances Atx3-
Induced Neurodegeneration
Expression of pathogenic human Atx3 from the transgene
UAS-SCA3trQ78 in the developing eye under the control of
the Gmr-Gal4 driver causes degeneration [8]. We identiﬁed a
transposon insertion in atx2 conferring Gal4-dependent
expression that greatly enhanced this toxicity (also reported
in [11]; see Materials and Methods for details of the screen).
To verify that up-regulation of atx2 was responsible for the
effect, we coexpressed a UAS-Atx2 transgene [22] together
with pathogenic Atx3 and conﬁrmed strongly enhanced eye
degeneration with loss of pigmentation and severe collapse of
the retina (Figure 1). Coexpression of Atx2 with a non-
pathogenic Atx3 construct bearing a normal-length polyglut-
amine repeat had no effect, such that the eyes looked the
same as those expressing only Atx2, as in Figure 1C
(unpublished data).
Since Atx2 expression can cause developmental effects [22],
we further examined neuronal integrity in an adult-onset
situation using the driver Rhodopsin-1-Gal4 (Rh1-Gal4), active
selectively in differentiated photoreceptor neurons (PR).
Adult ﬂies expressing pathogenic Atx3, normal ﬂy Atx2, or
both were born with the normal complement of seven visible
PR per unit eye, or ommatidium, as seen in pseudopupil
preparations (see Materials and Methods). Strong expression
of SCA3trQ78 induced progressive degeneration, from seven
PR declining to 3.7 6 0.22 PR by 18 d (Figure 2A and 2E).
Flies expressing only Atx2 also underwent retinal degener-
Figure 1. Atx2 Enhances Atx3-Dependent Neurodegeneration
External eye (top) and internal retina sections (bottom) of 1-d-old males. Internal degeneration is reflected in the thickness of the retina, indicated by
the yellow double-headed arrows.
(A) Control fly with driver only; eye is normal with a highly regular structure and normal pigmentation. Genotype: Gmr-Gal4/þ.
(B) Flies with a weakly expressing insertion of SCA3trQ78 have a normal external eye, although internally the retina is disorganized (compare to panel
[A]). Genotype: Gmr-Gal4/þ; UAS-SCA3trQ78(w)/þ.
(C) Flies expressing Atx2 have a mildly rough external eye surface, but no obvious degeneration externally or internally. Genotype: Gmr-Gal4/UAS-Atx2.
(D) Expression of Atx2 with SCA3trQ78 results in severe degeneration, with loss of pigmentation externally and collapse of the retina internally.
Genotype: Gmr-Gal4/UAS-Atx2; UAS-SCA3trQ78(w)/þ.
doi:10.1371/journal.pbio.0060029.g001
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Author Summary
Six forms of spinal cerebellar ataxia (SCA1,  2,  3,  6,  7, and  17)
are caused by dominant mutations in the respective genes. Patients
suffering from these different forms of SCA have similar symptoms
of progressive adult-onset neurodegeneration, and the same
causative mutation, a CAG repeat expansion encoding an expanded
run of polyglutamine. Although the affected proteins are distinct
and share no sequence similarity beyond the polyglutamine
domains, clinical and other observations hint at interactions
between the genes that cause different forms of SCA. Using
Drosophila as a model for human disease, we now detail an
interaction between the genes associated with SCA3 and SCA2. We
find that toxicity and neurodegeneration induced by pathogenic
forms of SCA3 depend on the normal activity of the fly counterpart
of the gene associated with SCA2, ataxin-2. This interaction depends
on a conserved protein-interaction motif of Ataxin-2, and a protein
that binds this motif, cytoplasmic poly(A)-binding protein (PABP),
also modulates SCA3 degeneration. These results suggest that the
normal roles of Ataxin-2 and PABP, potentially to regulate the
translation of select target mRNAs, are critical to SCA3 disease. These
studies also highlight how a fly model can serve to enhance and
extend intriguing clinical findings of the human disease.ation, but to a lesser extent (5.9 6 0.13 PR at 18 d; Figure 2B
and 2F; and see below). Coexpression of Atx2 with Atx3,
however, resulted in dramatically enhanced degeneration,
such that even by 6 d, there were only 4.7 6 0.15 PR (Figure
2C) compared to the near-normal eyes resulting from
expression of either protein alone (Figure 2A, 2B, and 2I).
By 18 d, these ﬂies had undergone nearly complete PR loss
(Figure 2G). At either 6 d or 18 d, PR loss due to coexpression
was greater than the sum of the deﬁcits caused by each
transgene alone, indicating a synergistic interaction.
These experiments were performed with a truncated
version of pathogenic Atx3 [8]. In mouse models and in
human SCA3 disease, the full-length pathogenic protein
undergoes proteolysis, yielding a similarly sized fragment
containing the polyglutamine tract that is thought to
contribute to disease [23]. To determine whether Atx2
interacted with the intact as well as truncated Atx3 protein,
we coexpressed Atx2 with full-length pathogenic Atx3
(SCA3Q84 [21]). Under conditions where Atx2 or SCA3Q84
alone had mild effects (6.3 6 0.16 PR and 6.97 6 0.02 PR,
respectively), coexpression of Atx2 with SCA3Q84 resulted in
strikingly severe degeneration (2.9 6 0.30 PR; Figure 2J).
Thus, synergistic enhancement of degeneration by Atx2 was
not limited to truncated versions of pathogenic Atx3, but
extended to the full-length protein. To further determine the
speciﬁcity of Atx2, we coexpressed Atx2 with two different
Huntington disease transgenes [24,25]. Atx2 dramatically
enhanced toxicity of an exon-1 Huntingtin (Htt) protein,
but had no effect on toxicity of a longer Htt fragment (Figure
S1). Cleavage of the Huntingtin protein contributes to disease
[26,27]; Atx2 may play a role by selectively promoting toxicity
of small Htt fragments.
For some dominantly acting disease proteins, up-regula-
tion of the normal version of the protein is sufﬁcient to cause
neurodegeneration clinically (for example, [28]) and in
animal models [9,29,30]. We were therefore interested in
the extent to which normal Atx2 could induce degeneration
in the adult in the absence of developmental effects. The
modest photoreceptor loss due to expression of Atx2 seen in
Figure 2B and 2F was more striking with stronger expression
of Atx2 from the transgenic line UAS-Atx2(s) [22]; even 1-d
ﬂies had mild but signiﬁcant loss of PR neurons (6.8 6 0.06,
vs. 7.0 6 0.01 PR in ﬂies expressing SCA3trQ78 only; p ¼
0.009) that progressed rapidly to 1.5 6 0.08 PR by 18 d
(Figure 2D and 2H). Therefore, up-regulation of normal Atx2
without a polyglutamine expansion causes severe, progressive
degeneration.
Reduction of Atx2 Activity Mitigates SCA3 Degeneration
Our ﬁndings demonstrated that up-regulation of Atx2
activity modulates SCA3 pathogenesis. To determine whether
Atx2 normally contributes to disease, we examined the effects
of reducing endogenous Atx2, which is expressed abundantly
in the adult ﬂy and is enriched in the head and brain [31].
Flies lacking 50% of normal Atx2 (heterozygous for a null atx2
allele) were examined for modulated SCA3trQ78 toxicity in
pseudopupil preparations with adult-onset expression. At 12
d, when Atx3 normally caused photoreceptor loss to 6.4 6
0.08 PR, reduction of Atx2 by 50% signiﬁcantly mitigated
degeneration (6.9 6 0.03 PR, Figure 3A). This ﬁnding was
conﬁrmed with a deletion removing atx2 (unpublished data).
Similar studies showed that ﬂies expressing full-length
Figure 2. Adult-Onset Degeneration due to Pathogenic Atx3 Is
Synergistically Enhanced by Atx2
(A–H) Pseudopupil preparations: each panel shows a field of seven unit
eyes (ommatidia); each ommatidium has seven visible photoreceptors
(PR) with light-gathering organelles (rhabdomeres) in a characteristic
trapezoidal pattern (e.g., green arrowhead in [A]). Examples of
degenerate ommatidia are highlighted in (E) by a yellow arrowhead (4
PR) and in (G) by a white arrowhead (1 PR). The mean number of PR 6
SEM per ommatidium (n ¼ 10 flies) is indicated at the bottom right of
each panel. (A–D) shows 6-d-old adults; (E–H) 18-d-old adults. (A and E)
Expression of SCA3trQ78 causes adult-onset PR loss over 18 d (from a
mean of 7.0 at 1 d to 3.7). Genotype UAS-SCA3trQ78(s)/þ; Rh1-Gal4/þ.( B
and F) Mild degeneration occurs with up-regulation of Atx2, to a mean of
5.9 PR at 18 d. Genotype UAS-Atx2/þ; Rh1-Gal4/þ. (C and G) Coexpression
of SCA3trQ78 with Atx2 causes severe PR loss (to a mean of 4.7 as early
as 6 d and to 1.3 at 18 d). Genotype UAS-Atx2/UAS-SCA3trQ78(s); Rh1-
Gal4/þ. (D and H) Strong expression of Atx2 alone causes severe
degeneration (to a mean of 1.5 PR at 18 d). Genotype: UAS-Atx2(s)/þ; Rh1-
Gal4/þ.
(I) Distribution of ommatidia in 6-d flies. The mean numbers of PR are
indicated schematically by the positions of arrowheads at top relative to
the x-axis (* p , 0.001 vs. SCA3trQ78 alone, p , 0.05 vs. Atx2 alone).
Genotypes as in (A–C), and mean PR counts are listed in lower right
corners of (A–C).
(J) The full-length pathogenic Atx3 protein also interacts synergistically
with Atx2: distribution of PR at 18–23 d; see text for mean PR counts, also
indicated by triangles at the top relative to the x-axis (* p , 0.001 vs.
SCA3Q84 and p , 0.05 vs. Atx2). Genotypes: (green) UAS-SCA3Q84/þ;
Rh1-Gal4/þ, (grey) UAS-Atx2/þ; Rh1-Gal4/þ, and (red) UAS-Atx2/UAS-
SCA3Q84; Rh1-Gal4/þ.
doi:10.1371/journal.pbio.0060029.g002
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heterozygous for an atx2 deletion (Figure S2).
To further address the role of endogenous atx2, we analyzed
neuronal integrity using the MARCM method [32], whereby
we could analyze small clones of neurons lacking atx2 activity.
Neuronal clones selectively marked with green ﬂuorescent
protein (GFP) (Figure 3B) were induced by mitotic recombi-
nation and were either atx2
þ or homozygous mutant for atx2.
When the UAS-SCA3trQ78 transgene was present, it was
expressed only in neuronal clones along with the GFP
marker. GFP
þ sensory neurons in the anterior wing margin
were examined in young adult ﬂies less than 8 h old and over
the subsequent 6 d, following marked neurons in individual
animals. In the absence of pathogenic Atx3, GFP
þ neurons
that were atx2
þ or homozygous for a null allele of atx2 were
retained at a similar rate: 83% of the former (unpublished
data) and 75% of the latter (Figure 3C) remained at 6 d. In
contrast, of GFP
þ neurons expressing SCA3trQ78 that were
present in young animals, only 13% were still detectable at 3
d, with all neurons lost by 6 d (Figure 3C and 3D). Strikingly,
SCA3trQ78-expressing neurons were dramatically retained if
they also lacked Atx2 function: 77% of these neurons were
present at 3 d and 40% were retained at 6 d (Figure 3C and
3E). Taken together, these studies indicate that normal
endogenous Atx2 activity facilitates Atx3-dependent toxicity,
with up-regulation of Atx2 enhancing and loss of Atx2
function dramatically slowing the progression of neuro-
degeneration caused by pathogenic Atx3.
Up-Regulation of Atx2 Accelerates Inclusion Formation by
Pathogenic Atx3
The formation of nuclear inclusions containing pathogenic
polyglutamine protein is a hallmark of polyglutamine
diseases, with the size and number of inclusions typically
correlating with disease severity in animal models [1–3]. In
retinal sections of animals expressing pathogenic Atx3 driven
by Rh1-Gal4, inclusions were sparse at 24 h but prominent by
4 d (Figure 4A and 4B). Up-regulation of Atx2—which
enhances Atx3 toxicity (Figures 1 and 2)—also accelerated
inclusion formation, such that at 24 h, Atx3-positive
inclusions were now prominent (Figure 4E). By 4 d, the
inclusions were similar to those of animals expressing
pathogenic Atx3 alone (compare Figure 4F to 4B).
Immunoblot experiments showed similar results (Figure
4J). At the 24-h time point, coexpression of normal Atx2 with
pathogenic Atx3 caused the early appearance of SDS-
insoluble Atx3 complexes that remain within the stacking
gel (compare lanes 1 and 2), presumably reﬂecting protein
Figure 3. Atx2 Function Is Required for Atx3-Induced Neurodegeneration
(A) Heterozygous loss of Atx2 suppresses SCA3trQ78 degeneration in the adult-onset model (*** p¼0.0007). Distribution of ommatidia in 12-d flies with
either normal Atx2 function or with heterozygous loss of Atx2 activity. Grey bars: UAS-SCA3trQ78(s)/þ; Rh1-Gal4/þ. Green bars: UAS-SCA3trQ78(s)/þ; Rh1-
Gal4/atx2
X1.
(B) Clones of sensory neurons in the anterior wing margin labeled with GFP by the MARCM technique [32]. Top, membrane-bound GFP marks neurons
expressing UAS-SCA3trQ78(s); bottom, GFP signal merged with bright-field image.
(C) Loss of Atx2 function in neuronal clones homozygous for atx2
 protects neurons from SCA3trQ78 toxicity. The retention of GFP
þneurons present in
newly born adults is plotted over time (mean 6 SEM, n¼10 flies per genotype). Whereas SCA3trQ78 expression alone results in rapid loss of neurons
(red), expression of SCA3trQ78 together with homozygous loss of atx2 results in significantly delayed neuron loss (green). Loss of atx2 alone has a
minimal effect (black).
(D and E) Images of two wings, at two time points each (,8 h and 3 d). Arrowheads flank GFP
þ neurons in the anterior margin in young animals. (D)
Wing from a fly expressing SCA3trQ78 in GFP
þneurons with normal Atx2 activity. Neurons visible when the fly was less than 8 h old (top) are no longer
detectable at 3 d (bottom). (E) Wing from a fly expressing SCA3trQ78 in GFP
þ neurons that also lack all Atx2 activity (homozygous for a null allele,
atx2
X1/atx2
X1); the GFP signal is maintained over 3 d. See Materials and Methods for genotypes for (B–E). Proximal is to the left in (B, D, and E).
doi:10.1371/journal.pbio.0060029.g003
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Ataxin-2 Modulates SCA3 Neurodegenerationaccumulations that correlate with the early appearance of
nuclear inclusions in cryosections. At the latter 4-d time
point, insoluble Atx3 complexes were present in extracts
from both groups (lanes 4 and 5). Differences in the
inclusions and high molecular weight complexes were due
to post-transcriptional causes, since Atx2 coexpression did
not affect the transcript levels of the SCA3trQ78 transgene
(Figure 4I).
Endogenous Atx2 protein was normally cytoplasmic
throughout the retina. By 4 d, however, endogenous Atx2
was detectable in most Atx3-positive nuclear inclusions
(Figures 4B–4D and S3), reminiscent of the Atx2 localization
to inclusions in SCA3 patients [7]. Up-regulated Atx2 protein
was not selectively recruited to inclusions, but remained
punctate along the length of photoreceptor neurons; this
pattern did not change over time or with coexpression of
SCA3trQ78 (Figure S4). Notably, in both SCA2 patients and a
SCA2 mouse model, pathogenic Atx2 with expanded poly-
glutamine is present in a similar cytoplasmic, punctate
pattern [33]. Whereas inclusions of pathogenic Atx3 co-label
for chaperones such as Hsp70, no such inclusions were
observed in ﬂies expressing only high levels of Atx2 (Figure
S4). Western blot analysis conﬁrmed that Atx2 protein levels
were not affected by pathogenic Atx3 (unpublished data). In
summary, endogenous Atx2 is recruited to nuclear inclusions
formed by pathogenic Atx3, as in SCA3 patients.
The Interaction between Atx2 and Pathogenic Atx3 Is
Dependent on the PAM2 Motif of Atx2
To provide insight into the mechanism by which Atx2
modulates polyQ toxicity, we determined whether the
conserved 12-amino acid PAM2 motif of the Atx2 protein
was required for enhancement of SCA3 toxicity. The PAM2
motif is required for Atx2 to associate with PABP, and
together with the RNA-binding Lsm domain, it mediates the
colocalization of Atx2 with PABP in polyribosomes [16]. We
tested whether a construct lacking the conserved PAM2
domain, UAS-Atx2DP [16], could modulate Atx3 toxicity.
Atx2DP retains partial Atx2 function, since it delays
embryonic lethality caused by complete loss of atx2 function
[16]. The Atx2DP transgenic line expressed the protein at a
level comparable to that of the strongly expressing Atx2(s)
line (Figure S5). Expression of Atx2DP driven by Gmr-Gal4
caused a disrupted eye phenotype distinct from that caused
by up-regulation of normal Atx2: black patches were present
on the surface, and the underlying retina was disorganized
although intact, showing no evidence of degeneration (Figure
5A). In striking contrast to normal Atx2 protein, coexpres-
sion of Atx2DP failed to enhance SCA3trQ78 toxicity: the
ﬂies showed an eye phenotype identical to that caused by
Atx2DP alone (Figure 5B; compare to Figure 1D).
We conﬁrmed this ﬁnding by examining interactions
between Atx2DP and pathogenic Atx3 in the adult, uncom-
plicated by any developmental effects. Coexpression of
Atx2DP and SCA3trQ78 driven by Rh1-Gal4 caused a mild
adult-onset photoreceptor loss at 6 d (6.7 6 0.06 PR; Figure
5D) that was similar to that caused by SCA3trQ78 alone (6.9
6 0.02 PR; see Figure 2A), and strikingly less severe than
that caused by coexpression of SCA3trQ78 with normal Atx2
(p , 0.001; see Figure 2C). The accelerated appearance of
inclusions caused by up-regulated normal Atx2 was also
dependent on the PAM2 domain, since coexpression of
Atx2DP with SCA3trQ78 did not alter the time course of
inclusion formation (compare Figure 4G to 4E). Moreover,
coexpression of Atx2DP did not cause the early appearance of
SDS-insoluble complexes containing Atx3 (Figure 4J, com-
Figure 4. Atx2 Alters the Time Course of and Colocalizes with Pathogenic Atx3 Inclusions
Retinal cryosections at (A, E, and G) 24 h and (B–D, F, and H) 4 d. (A–D) Flies expressing SCA3trQ78 only (genotype UAS-SCA3trQ78(s)/þ; Rh1-Gal4/þ). (E
and F) Flies coexpressing SCA3trQ78 and Atx2 (UAS-SCA3trQ78(s)/UAS-Atx2; Rh1-Gal4/þ). (G and H) Flies coexpressing SCA3trQ78 and Atx2DP( UAS-
SCA3trQ78(s)/þ; Rh1-Gal4/UAS-Atx2DP). (A, B, and E–H) Pathogenic Atx3 protein is tagged with the HA epitope and visualized with anti-HA (magenta).
Up-regulation of Atx2, but not of Atx2DP lacking the PAM2 motif, results in the early onset of inclusions at 24 h. (C) Same section as in (B), stained for
endogenous Atx2 (green). (D) Merged images show colocalization of Atx2 in the inclusions. See Figure S3 for larger images, including DAPI staining,
that show nuclear localization and orientation within the retina.
(I) Coexpression of SCA3trQ78 with Atx2 does not significantly change SCA3 mRNA levels (p¼0.21). Quantitative real-time PCR comparing mean relative
levels 6 SEM of SCA3trQ78 mRNA from heads of 1–2-d flies, from two separate cDNA preparations for each group, normalized to coexpression with
control transgene UAS-eGFP. Genotypes: UAS-SCA3trQ78(s)/UAS-eGFP; Rh1-Gal4/þ, and UAS-SCA3trQ78(s)/UAS-Atx2; Rh1-Gal4/þ.
(J) Immunoblot of the Atx3 protein (anti-HA, top) and loading control b-actin (bottom). Lanes 1–3, head extracts from 24-h flies; lanes 4–6, heads
extracts from 4-d flies. Lanes 1 and 4, coexpression of SCA3trQ78 and control transgene (UAS-eGFP); lanes 2 and 5, coexpression of SCA3trQ78 and Atx2;
lanes 3 and 6, coexpression of SCA3trQ78 and Atx2DP (genotypes in [A], [E], [G]). At 24 h, only flies coexpressing Atx2, but not Atx2DP, have high-
molecular weight complexes containing Atx3 visible in the stacking gel portion (s) of the blot.
doi:10.1371/journal.pbio.0060029.g004
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the PAM2 motif of Atx2 is required for the enhancement of
pathogenic Atx3-dependent degeneration as well as for the
early appearance of Atx3 inclusions and insoluble complexes.
Adult-onset expression of Atx2 lacking the PAM2 motif
alone also did not cause neurodegeneration: even at 18 d, ﬂies
expressing Atx2DP had a normal retinal structure (7.0 6 0.01
PR, Figure 5C; compare to normal Atx2 expressed at an
equivalent level, which results in 1.5 6 0.08 PR, Figure 2H).
Thus the PAM2 motif is required for the inherent toxicity of
Atx2 when it is up-regulated in the adult eye.
The Atx2-Binding Protein PABP Modulates
Neurodegeneration
PABP is the only known protein to date that interacts
directly with Atx2 through the PAM2 motif [13,14,16];
therefore, given the important role of the PAM2 motif
described above, we asked if PABP played a role in SCA3
neurodegeneration. Heterozygosity for the available pabp
allele had no effect on Atx3 toxicity, although this allele is
unlikely to be a complete loss of function [34]. We then tested
a deletion chromosome that removed the pabp gene,
comparing to appropriate control lines (see Materials and
Methods). Flies expressing pathogenic Atx3 that were
heterozygous for this deletion showed dramatically enhanced
photoreceptor loss (1.6 6 0.07 PR, compared to the control
3.5 6 0.16 PR; Figure 6A). Control experiments conﬁrmed
that the deletion alone, in the absence of pathogenic Atx3,
did not cause neurodegeneration (unpublished data). In
contrast to the loss-of-function situation, overexpression of
PABP signiﬁcantly suppressed neurodegeneration (from 4.2
6 0.18 PR to 6.0 6 0.08 PR; Figure 6A). These observations
indicated that PABP has the opposite activity as Atx2 with
respect to Atx3-dependent neurodegeneration: whereas Atx2
enhances the toxicity of Atx3, PABP is protective.
We then tested whether PABP could modulate the
degeneration induced by strong expression of Atx2 as shown
in Figure 2D and 2H. Decreased PABP function enhanced
Atx2-dependent photoreceptor loss (from 1.7 6 0.09 PR to
1.3 6 0.06 PR); likewise, up-regulation of PABP protected
against photoreceptor degeneration (2.9 6 0.16 PR to 5.1 6
0.19 PR; Figure 6B). These studies suggest that the toxicity of
Atx2 is mitigated by physical association with PABP, and they
are consistent with PABP also playing a crucial role in the
Atx2–Atx3 interaction. Together with our results demonstrat-
ing the crucial role of the PAM2 motif, these data highlight
the importance of the normal biological activity of Atx2 and
of PABP in modulating the toxicity of pathogenic Atx3.
Discussion
Our studies in Drosophila reveal that the toxicity of
pathogenic human Atx3 is critically dependent on Atx2
activity. Reduction of endogenous Atx2 function mitigated
Atx3-induced neurodegeneration, and up-regulation of Atx2
synergistically enhanced degeneration. We also reveal the
roles in neural integrity played by the non-polyglutamine
PAM2 motif of Atx2 and by PABP, which binds to Atx2 via this
motif.Thesedataareconsistentwithandexpanduponclinical
ﬁndings suggesting interactions between Atx2 and Atx3 in
human disease [5–7]. In the ﬂy, endogenous Atx2 colocalized
with pathogenic Atx3 in inclusions, as seen in human patients
[7], with up-regulation of Atx2 enhancing Atx3 toxicity
concomitant with a faster onset of inclusions and of SDS-
insoluble complexes. These ﬁndings suggest that therapeutic
approaches to modulate Atx2 activity may be effective against
multiple disease situations, including SCA2 and SCA3.
Interestingly, we ﬁnd that normal Atx2 is toxic, causing
degeneration when up-regulated. Previous animal models
Figure 5. The PAM2 Motif of Atx2 Is Required for Enhancement of Atx3
Degeneration and for Atx2 Toxicity
(A and B) External eye and internal retinal sections. Retinal thickness is
indicated by double-headed yellow arrows. (A) Expression of Atx2
lacking the PAM2 motif (Atx2DP) causes a disrupted eye with (top)
external roughness and dorsal discoloration and (below) disorganized
internal structure. Genotype: Gmr-Gal4/þ; UAS-Atx2DP/þ. (B) Co-expres-
sion of Atx2DP with SCA3trQ78 does not enhance SCA3trQ78
degeneration; the eye looks identical to that of flies expressing Atx2DP
only. Genotype: Gmr-Gal4/þ; UAS-SCA3trQ78(w)/UAS-Atx2DP.
(C and D) Pseudopupil preparations to highlight internal retinal
degeneration. (C) Flies expressing Atx2DP maintain a normal retina over
time, with a mean of seven PR (18 d shown, genotype: Rh1-Gal4/UAS-
Atx2DP). (D) Coexpression of Atx2DP with SCA3trQ78 has minimal effect
on SCA3trQ78 degeneration, with a mean of 6.7 PR (6 d, UAS-
SCA3trQ78(s)/þ; Rh1-Gal4/UAS-Atx2DP); normally SCA3trQ78 expression
by itself results in a mean of 6.9 PR at 6 d (see Figure 2A).
doi:10.1371/journal.pbio.0060029.g005
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with SCA1 and Parkinson’s disease—Ataxin-1 and a-Synu-
clein, respectively—are also toxic when expressed at sufﬁ-
ciently high levels [9,29,30]. Expansion of the polyglutamine
domain in Ataxin-1 or Parkinson disease-associated missense
mutations of a-Synuclein presumably lead to increased levels
of the respective proteins, sufﬁciently high to elicit disease.
Up-regulation of Drosophila Atx2 may cause degeneration for
similar reasons. Our studies further reveal that neuronal
toxicity of Atx2 depends on its PAM2 motif—an observation
with an interesting parallel to Ataxin-1, the protein that
causes SCA1: an expanded polyglutamine repeat in Ataxin-1
is not sufﬁcient to cause neurodegeneration in mouse models
for SCA1, but rather pathogenic Ataxin-1 also requires its
AXH domain to cause disease [35].
The importance of the PAM2 motif for Atx29s toxicity and
for the enhancement of Atx3 toxicity suggests a clue to the
mechanism of the interaction. The PAM2 motif has been
shown to bind speciﬁcally to the PABC domain [13], with
PABP being currently the only known PABC-containing
protein that interacts with Atx2. PABP is a ubiquitously
expressed and essential protein that binds to the polyadeny-
lated tails of mRNAs and is required for their translation.
Furthermore, biochemical and genetic data support an
interaction between Atx2 and PABP across many species
[15,16,36]. Data from C. elegans indicate that loss of Atx2 can
result in misregulated translation [15], and in yeast Atx2
negatively regulates PABP [36]. Consistent with these ﬁndings,
we have shown that Atx2 and PABP have opposing activities in
modulating the progression of SCA3 toxicity in ﬂies.
Protein interaction studies indicate that Atx2 and Atx3 do
not interact directly; in a survey of the interaction network of
ataxia-associated proteins, Atx2 and Atx3 were separated by
four nodes [12]. However, the known function of PABP and
the role of the PAM2 motif in localizing Atx2 to polyribo-
somes [16] together indicate that Atx2 and PABP modulate
translation of speciﬁc transcripts. Since Atx2 is sufﬁcient to
cause neurodegeneration in the absence of pathogenic Atx3
(see Figure 2D and 2H), Atx3 mRNAs cannot be the sole
target of Atx2–PABP interactions, and additional transcript
targets must be critical to normal neuronal integrity.
Our experiments in Drosophila demonstrate that the ﬂy
provides an outstanding complement to clinical observations
and to vertebrate disease models. In this case, the ﬂy has
highlighted the signiﬁcance of intriguing interactions be-
tween the genes that cause SCA2 and SCA3 diseases that can
be supported by molecular and genetic ﬁndings. More
speciﬁcally, these data indicate striking crosstalk between
the pathways of normal Atx2 function and pathogenic Atx3
activity. Further understanding of both the Atx2 and Atx3
pathways may reveal insight into maintenance of neuronal
integrity in a number of distinct disease situations.
Materials and Methods
Fly stocks. Truncated and full-length UAS-SCA3 transgenes have
been previously described [8,21]. The following stocks were kind gifts
from Terry Satterﬁeld and Leo Pallanck: UAS-Atx2 (a.k.a. UAS-
Atx2.1B), UAS-Atx2(s) (a.k.a. UAS-Atx2.4), UAS-Atx2DP (a.k.a. UAS-
Atx2DC1A3), and FRT82B atx2
X1. UAS-Htt-ex1Q93 [24] was a gift from
Larry Marsh, Leslie Thompson (University of California Irvine), and
Larry Goldstein (University of California San Diego), and is termed
Htt174(Q93) in Figure S1; UAS-HttQ128 [25] was a gift of Troy
Littleton (MIT), and is termed Htt676(Q128). MARCM stocks (see
below) and UAS-PABP [34] were obtained from the Bloomington
Stock Center. EP(3)3145, Df(2R)ED3610, P[5-SZ-3325], P[CB-6101–3],
Df(3R)ED5705, P[5-SZ-3416], and P[CB-0741–3] were obtained from
the Szeged Stock Center. P[CB-6101–3] and P[5-SZ-3325] were P
element insertions used to construct Df(2R)ED3610, which deletes
pabp, and P[5-SZ-3416] and P[CB-0741–3] were used to construct
Df(3R)ED5705, which deletes atx2 [37]. Both P insertions of a pair
were equivalent controls for comparisons to the respective deletions
in the experiments; results are shown for P[5-SZ-3325] only in Figure
6 for simplicity. All experiments were performed at 25 8C. The
EP(3)3145 allele of atx2 was identiﬁed in the part of the screen
Figure 6. The Atx2 Binding Partner PABP Modulates Neurodegeneration
Distributions of ommatidia from pseudopupil analysis; mean PR counts indicated by the positions of triangles above the graphs (see text for precise
values).
(A) Flies expressing pathogenic Atx3 at 18d. Top: red bars show distribution of ommatidia in flies heterozygous for a deletion removing pabp (Df(pabp))
compared to flies heterozygous for a P element used to synthesize the deletion (grey; P[SZ]). The loss of 50% of PABP activity (red) results in significant
enhancement of degeneration (*** p , 10
 4). Genotypes: UAS-SCA3trQ78(s)/P[5-SZ-3325]; Rh1-Gal4/þ or UAS-SCA3trQ78(s)/Df(2R)ED3610; Rh1-Gal4/þ.
Bottom: up-regulation of PABP (green) suppresses degeneration induced by SCA3trQ78 (*** p , 10
 4). Genotypes: UAS-SCA3trQ78(s)/þ; Rh1-Gal4/þ or
UAS-SCA3trQ78(s)/þ; Rh1-Gal4/UAS-PABP.
(B) Strong expression of Atx2 in 6-d flies. Top, degeneration by Atx2 (grey) is enhanced by reduced levels of PABP (red; ** p ¼ 0.003). Bottom, up-
regulation of PABP (green) suppresses Atx2-mediated degeneration (*** p , 10
 4). Genotypes as in (A), except with UAS-Atx2(s) instead of UAS-
SCA3trQ78.
doi:10.1371/journal.pbio.0060029.g006
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were crossed to a series of enhancer P (EP) insertions that confer
Gal4-dependent expression on adjacent genes [39].
External eye microscopy. For eye pictures in Figures 1 and 5, we
used a Leica Z16-Apo A motorized zoom microscope system with
DFC420 digital camera and Leica Application Suite Montage module
software (Leica Microsystems).
Pseudopupil preparations. Pseudopupil preparations were per-
formed as described [40] with w
þ male ﬂies. The Rh1-Gal4 driver is
active in the outer six PR neurons of each unit eye (ommatidium). As
an indicator of the number of PR neurons, rhabdomeres were
counted in 10–20 ommatidia of n ¼ 10 ﬂies of each genotype. Mean
PR counts 6 standard error of the mean (SEM) per ommatidium are
indicated in the ﬁgures and text. Statistical analysis was performed
with Prism software. The two-tailed Mann Whitney test was used to
calculate the p-value when comparing the results of pseudopupil
preparations between two groups. In experiments with three groups
(in Figures 2I, 2J, and S2, and for a comparison of phenotypes due to
SCA3trQ78 alone, with Atx2 or with Atx2DP, stated in the text
discussing Figure 5D), the Kruskal-Wallis test was performed followed
by Dunn post-tests.
Quantitative real-time PCR. Quantitative real-time PCR was per-
formed in triplicate on each cDNA sample with an Applied Biosystems
7500 Fast system. Duplex PCRs were performed in single wells with
human ATXN3 forward primer 59CAGGACAGAGTTCACATCCATGT,
reverse primer 59GCCTTACCTAGATCACTCCCAAGT, and FAM-la-
beled Taqman probe 59CCAGCCACCAGTTCAG (Applied Biosystems
assay by design), and with human 18s rRNA as the internal control (the
Drosophila sequence is identical; primers and VIC-labeled probe, Applied
Biosystems #4319413E). Template was random-primed cDNA prepared
with Superscript III (Invitrogen) from RNA made from 80–115 male
heads (Qiagen RNeasy). Before PCR, cDNA was treated with Turbo DNase
(Ambion) to remove genomic DNA. Quantitative PCR results were
analyzed with the two-tailed t-test (Prism software).
Immunoblots. Heads were extracted in Laemmli buffer and
samples were run on 12% polyacrylamide gels and blotted overnight
at 20 V at 4 8C (all reagents from Bio-Rad). Antibody dilutions and
block were 3% dry milk in Tris-buffered saline with Tween (Sigma).
Imaging was performed with ECLþ (GE Healthcare) on a Fuji LAS-
3000 system. Antibodies: rat anti-HA-peroxidase (Roche; 1:500),
rabbit anti-Atx2 [22] (1:10,000), mouse anti-tubulin (Developmental
Studies Hybridoma Bank; 1:2,000), mouse anti-b-actin (Abcam;
1:20,000) with secondaries anti-rabbit-peroxidase and anti-mouse-
peroxidase (Chemicon; 1:2,000).
Marked wing margin clones. Marked wing margin clones were
induced using previously developed reagents and procedures [32].
MARCM stock females were crossed to experimental FRT82B males
and allowed to lay eggs for approximately 18 h, at which point
parental ﬂies were cleared from the vials. Progeny were of genotype
Elav-Gal4 hsFLP UAS-mcd8GFP/Y; [UAS-SCA3trQ78(s)]/þ; FRT82B tubP-
Gal80/FRT82B [atx2
X1]. The presence of UAS-SCA3trQ78 or atx2
X1
varied between experimental groups, as indicated by brackets.
Mitotic recombination between the FRT sites was induced in progeny
larvae 3 d later by submerging vials for 50 min in a 37 8C water bath.
About half of the resulting daughter cells lacked Gal80 (a Gal4
inhibitor), and if they or their progeny were neurons, the neuronal
driver Elav-Gal4 was free to drive expression of the GFP marker and
(if present) of SCA3trQ78 as well. If the atx2
X1 mutation was present
on the FRT82B chromosome as indicated above, these daughter cells
and their progeny were homozygous for this null atx2 allele.
Histology. Flies in Figures 1, 5, and S1 were 1d w
1118 males. Retinal
tissue was visualized by autoﬂuorescence in horizontal parafﬁn
sections [29]. Antibody staining was performed on frontal cryosec-
tions as described [40]. The SCA3trQ78 transgene encodes a protein
tagged with the HA epitope [8]. Antibodies used were mouse anti-HA
(5B1D10, Zymed, 1:100); rabbit anti-Atx2 [22] (1:5,000); and mouse
anti-hsc70/hsp70 (SPA-822, Stressgen, 1:100). Secondary antibodies
used were anti-mouse-alexa488, anti-mouse-alexa594, and anti-
rabbit-alexa594 (1:100; Invitrogen-Molecular Probes).
Supporting Information
Figure S1. Atx2 Enhances Toxicity of the Exon-1 Model of
Huntington Disease
Two Drosophila models for Huntington disease comprise different N-
terminal portions of human Huntingtin, a protein of over 3,000
amino acids. One transgene expresses the ﬁrst exon of the Htt gene,
comprising the N-terminal 174 residues including a polyQ expansion
of Q93, termed here Htt174(Q93) [24]. The second expresses the ﬁrst
676 residues of Htt including a repeat expansion of Q128,
Htt676(Q128) [25].
(A–D) External eye and internal retinal sections. Double-headed
yellow arrows indicate retinal depth, which highlights internal
degeneration. (A) Expression of Htt174(Q93) caused internal retinal
degeneration (genotype Gmr-Gal4/UAS-Htt-ex1Q93)t h a t( B )w a s
enhanced by Atx2 up-regulation (Gmr-Gal4 UAS-Atx2/UAS-Htt-
ex1Q93) (compare to control in Figure 1A and to Figure 1C, showing
the mild developmental defect of Atx2 alone). (C) Expression of
Htt676(Q128) (Gmr-Gal4/UAS-HttQ128) caused degeneration that was
not changed upon (D) up-regulation of Atx2 (Gmr-Gal4 UAS-Atx2/UAS-
HttQ128).
Found at doi:10.1371/journal.pbio.0060029.sg001 (5.2 MB TIF).
Figure S2. Degeneration due to Full-Length Pathogenic Atx3 Is
Partially Suppressed by the Loss of 50% of Atx2 Activity
Adult-onset degeneration analyzed by pseudopupil method showing
the distribution of unit eyes or ommatidia at 43–45 d. Df(3R)ED5705
is a deletion that removes atx2; P[5-SZ-3416] and P[CB-0741–3] are
isogenic P element insertion lines that were used to synthesize the
deletion [37]. Mean numbers of PR 6 SEM per ommatidium for n ¼
10 ﬂies, indicated schematically at top by arrowheads at the
appropriate place along the x-axis, are as follows: P[5-SZ-3416]
control, in black: 3.0 6 0.13; P[CB-0741–3] control, in grey: 3.5 6
0.15; Df(3R)ED5705, in green: 5.0 6 0.13 (** p , 0.001 vs. P[5-SZ-
3416] and p , 0.01 vs. P[CB-0741–3]). Genotypes: black, P[5-SZ-3416]/
Rh1-Gal4 UAS-SCA3Q78; grey, P[CB-0741–3]/Rh1-Gal4 UAS-SCA3Q78;
and green, Df(3R)ED5705/Rh1-Gal4 UAS-SCA3Q78.
Found at doi:10.1371/journal.pbio.0060029.sg002 (225 KB TIF).
Figure S3. Atx2-Atx3 Colocalization
Larger regions of the same sections shown in Figure 4B–4D of the
main text, with Rh1-Gal4 driving expression of pathogenic Atx3 only.
DAPI stain (top) highlights the orientation and nuclear localization of
inclusions containing pathogenic Atx3 (red, anti-HA) and endoge-
nous Atx2 (green, anti-Atx2).
L, nuclei of the lamina, the brain structure to which most
photoreceptors synapse; R, retinal nuclei, including those of photo-
receptor neurons R1–R7, are concentrated at the outer edge of the
retina; R8, nuclei of photoreceptors R8, which are not visible in
pseudopupil preps.
Found at doi:10.1371/journal.pbio.0060029.sg003 (6.0 MB TIF).
Figure S4. Distribution of Up-Regulated Atx2 in Retinal Cryosections
Males with Rh1-Gal4 driving the following UAS transgenes: (A) Atx2
only, (B–G) Atx2 and SCAtrQ78(s), (H–J) SCA3trQ78(s) only, (K–M)
Atx2(s) only. (A, B, E, and K) Anti-Atx2 in green; (C and F) anti-HA
detecting pathogenic Atx3 in magenta; (I and L) anti-hsc70/hsp70 in
magenta. (D, G, J, and M) merged green and magenta images. (A, B,
and E) The pattern of up-regulated Atx2 is similar over time and with
coexpression of SCAtrQ78(s). (D and G) Up-regulated Atx2 coloc-
alizes with pathogenic Atx3, but is also widely expressed throughout
the depth of the retina. (H–J) An endogenous chaperone strongly
colocalizes with pathogenic Atx3 in inclusions, but (K–M) is more
uniformly diffuse in the presence of strong Atx2 up-regulation.
Found at doi:10.1371/journal.pbio.0060029.sg004 (6.7 MB TIF).
Figure S5. Expression Levels of Atx2 Transgenes
Each lane contains an extract of heads from 1-d males, bearing either
the Gmr-Gal4 or the Rh1-Gal4 driver and the indicated UAS
transgene. Endogenous levels of Atx2 (lane Rh1.eGFP) were not
consistently detectable. Asterisks indicate nonspeciﬁc bands. Quanti-
ﬁcation of Atx2 transgene levels of Rh1-Gal4–dependent expression
indicated that the Atx2(s) and Atx2DP insertions expressed at levels
2.3 6 0.6-fold and 2.5 6 0.6-fold stronger than Atx2, respectively (n¼
3 independent experiments, quantiﬁcation with ImageJ software).
Atx2 expression resulting from Gmr-Gal4 is higher than from Rh1-
Gal4, since Gmr-Gal4 is active in most cells in the developing eye
tissue, whereas Rh1-Gal4 is expressed in only six photoreceptor
neurons of each ommatidium.
Found at doi:10.1371/journal.pbio.0060029.sg005 (10.1 MB TIF).
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Note Added in Proof
While this manuscript was under review, Al-Ramahi et al [41] reported
similar activity of Atx2 on a ﬂy SCA1 model that further supports the idea of
interactions among SCA genes.
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